Metrics

Agreed Proposals

The table below provides details of approved Research Proposals that have signed Data Sharing Agreements.

Click here to download the Agreed Proposals Report.

Proposal number Sponsor/Funder Title Institution Lead researcher  
611 GSK Long-acting beta2-agonists for chronic obstructive pulmonary disease Cochrane Airways Group, at St George's University of London Kayleigh Kew Further Details
628 GSK Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada Arnoud J. Templeton, MD Further Details
631 GSK Predictors of BPH Progression Duke University Dr. Stephen Freedland, MD Further Details
637 GSK Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial New York University school of Medicine, NY, NY Sripal Bangalore Further Details
639 GSK Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease St Luke's-Roosevelt Hospital of the Columbia University of Physicians and Surgeons Saurav Chatterjee MD Further Details
645 GSK The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension New York Medical College-Metropolitan Hospital Center, Department of Medicine, New York, NY Partha Sardar Further Details
646 GSK Factors influencing immune response and patient outcomes following influenza vaccination. Health Protection Research Group, University of Nottingham Dr Subhadra Rajanaidu Further Details
647 GSK Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials Institute for Clinical Research and Health Policy Studies, Tufts Medical Center David M. Kent, MD, MSc Further Details
651 GSK Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children. P95 Pharmacovigilance and Epidemiology Services Thomas Verstraeten Further Details
653 GSK Functional Estimation of Interventional Effects Department of Economics, Indiana University, Bloomington, Professor Sungkyunkwan University, Professor of Economics Joon Park Further Details
First 1 2 3 4 5  ... Last